Application of the AMeX method to the evaluation of HER-2 status in breast carcinomas: comparison with the results of HercepTest.
The recent development of the recombinant humanized monoclonal antibody against HER-2 oncoprotein requires a simple and accurate method for the evaluation of HER-2 status in patients with breast cancers. We here report that the evaluation of the HER-2 status is improved by the use of the acetone-methanol-xylene (AMeX) method. Compared with an ordinary test of HercepTest, 25 out of 63 cases (39.7%) were scored upwards by the AMeX method. In addition, the HER-2 gene amplification was easily estimated by fluorescence in situ hybridization (FISH) using the AMeX method. Thus, the AMeX method is likely to provide more improved data about the HER-2 status in breast carcinoma specimens.
Mizogami
Masayo
M
Division of Pathological Diagnosis, Jichi Medical School Hospital, and Department of Pathology, Jichi Medical School, Tochigi, Japan.
Sakurai
Shinji
S
Kikuchi
Midori
M
Ohta
Kenichi
K
Sakurai
Tatsuo
T
Tanaka
Akira
A
Saito
Ken
K
D001943:Breast Neoplasms / Q000737:chemistry / Q000175:diagnosis / Q000235:genetics*; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000737:chemistry / Q000175:diagnosis / Q000235:genetics*; D005260:Female; D018734:Genes, erbB-2 / Q000235:genetics*; D016591:Histocytological Preparation Techniques / Q000379:methods*; D006801:Humans; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D011933:Reagent Kits, Diagnostic; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis / Q000235:genetics*; D015203:Reproducibility of Results
D011933:Reagent Kits, Diagnostic; D018719:Erb-b2 Receptor Tyrosine Kinases